Professional Summary
Ms. Kim specializes in intellectual property litigation, with a focus on patent litigation. A number of these have concerned the introduction of generic pharmaceuticals into the U.S. marketplace under the Hatch-Waxman Act, including omeprazole, pantoprazole, bupropion hydrochloride ER, terazosin hydrochloride, a generic version of Tri-Cyclen^®, and a generic version of Ortho-Novum 7/7/7^®.

Trials in which Ms. Kim has participated include a patent litigation concerning bupropion hydrochloride ER (full bench trial); a patent litigation involving papermaking equipment (full jury trial); and a copyright litigation. Other experience includes a Citizen Petition to the FDA relating to Ticlopidine hydrochloride; opinion letters in various arts; work with corporate counsel on the initial public offering of the securities of a generic pharmaceutical company; and trade dress, trademark, and copyright litigation.

Education
J.D., Fordham University School of Law, 1991
B.S., Industrial Engineering, Lehigh University, 1984

Admissions
New York
U.S. Court of Appeals for the Federal Circuit
U.S. District Courts for the Southern, Eastern, and Western Districts of New
York and the Western District of Wisconsin
U.S. Patent and Trademark Office

Decisions
Savient Pharmaceuticals, Inc. v. Sandoz, Inc., No. 2007-1081, 2007 U.S. App. LEXIS 2800, 2007 WL 419358 (Fed. Cir. Jan. 25, 2007) (order dismissing proceeding).

Dey LP v. IVAX Pharm. Inc., 233 F.R.D. 567 (C.D. Cal. 2005).

Glaxo Wellcome Inc., v. Eon Labs Mfg., Inc., No. 00-Civ-9089, 2003 U.S. Dist LEXIS 14680, 2003 WL 22004874 (S.D.N.Y. Aug. 22, 2003).

In re Omeprazole Patent Litigation, 265 F. Supp. 2d 213 (S.D.N.Y. 2003).

Glaxo Wellcome Inc., v. Eon Labs Mfg., Inc., No. 00-Civ-9089, 2002 U.S. Dist. LEXIS 14950, 2002 WL 1874831 (S.D.N.Y. Aug. 13, 2002).